A Archives | Report Store | Pharma intelligence

show blocks helper

Sort by Price
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products ascending

Display 15 Products per page

AGS-003

$10,000.00

AGS-003 (Argos Therapeutics/Kyowa Hakko Kirin) is a cancer vaccine in development for the first-line treatment of metastatic renal cell cancer (RCC) in combination with Sutent (sunitinib; Pfizer).
February 5, 2016
Select options
Atripla

$10,000.00

Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.
December 11, 2015
Select options
ABBV-066

$10,000.00

ABBV-066 (risankizumab; AbbVie/Boehringer Ingelheim) is a humanized anti-interleukin(IL)-23 subunit p19 monoclonal antibody that binds and neutralizes the p19 subunit of IL-23.
August 26, 2016
Select options
Aducanumab

$10,000.00

Aducanumab (Biogen/Eisai) is an intravenous-infused, fully human recombinant immunoglobulin G1 monoclonal antibody.
September 29, 2016
Select options
Actemra

$10,000.00

Actemra (tocilizumab; Roche/Chugai), known as RoActemra in Europe, is a first-in-class humanized interleukin-6 receptor monoclonal antibody.
March 24, 2015
Select options
Adempas

$10,000.00

Adempas (riociguat; Bayer/Merck & Co) is a first-in-class drug that activates soluble guanylyl cyclase (sGC), a key enzyme in nitric oxide-mediated vasodilation of vascular smooth muscle cells.
October 29, 2018
Select options
Arcapta

$10,000.00

Novartis has developed Arcapta (indacaterol; marketed as Onbrez outside the US) for use in its Breezhaler/Neohaler dry-powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD).
July 31, 2018
Select options
Azeliragon

$10,000.00

Azeliragon is an orally available small molecule that acts as an inhibitor of the receptor for advanced glycation endproducts (RAGE).
September 2, 2016
Select options
ALKS 5461

$10,000.00

ALKS 5461 (buprenorphine/samidorphan; Alkermes) had previously seemed an exciting antidepressant
candidate, as its novel opioid-targeting mechanism translated into a large and rapid symptomatic
effect in a Phase II study.
April 21, 2017
Select options
Alofisel

$10,000.00

Alofisel (darvadstrocel; TiGenix/Takeda) is a suspension of allogeneic expanded adipose-derived stem cells via intralesional injection.
August 2, 2018
Select options
ADI-PEG 20

$10,000.00

ADI-PEG 20 (PEG-arginine deiminase; Polaris Group) is a bacterial enzyme that degrades the amino acid, arginine.
July 24, 2017
Select options
Aricept

$10,000.00

Aricept (donepezil; Eisai/Pfizer) has been the gold standard in the treatment of all stages of
Alzheimer’s disease for more than a decade.
September 2, 2016
Select options
Lyxumia

$10,000.00

Lyxumia (lixisenatide; Sanofi) is a member of the glucagon-like peptide-1 (GLP-1) agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas.
November 7, 2017
Select options
Acalabrutinib

$10,000.00

Acalabrutinib (AstraZeneca/Acerta) is a novel, orally available, second-generation Bruton’s tyrosine kinase (BTK) inhibitor with potential antineoplastic activity.
May 12, 2017
Select options
Alpelisib

$10,000.00

Alpelisib is a p110-alpha isoform-specific PI3K inhibitor. PI3K signaling plays a fundamental role in tumorigenesis, governing cell proliferation, survival, and motility, as well as angiogenesis.
February 5, 2016
Select options

A

A

AGS-003

Atripla

ABBV-066

Aducanumab

Actemra

Adempas

Arcapta

Azeliragon

ALKS 5461

Alofisel

ADI-PEG 20

Aricept

Lyxumia

Acalabrutinib

Alpelisib